Navigation Links
Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
Date:6/29/2009

b>About Russell

Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell had more than $136 billion in assets under management as of March 31, 2009, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.celltherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of our securities. Specifically, the risks and uncertainties include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and CTI in particular, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing products, CTI's ability to continue to raise capital as needed to fund its operations, the impact of CTI's inclusion in the Russell 3000 Index, Russell 2000(R) Index and the Russell Global Index and the risk factors listed or described from time to time in CTI's filings
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
2. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
3. PTC Therapeutics Receives $2.6 Million in Government Grants
4. Cell Therapeutics on Preliminary List of Additions to Russell 3000(R) Index and Russell Global(R) Index
5. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
6. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
7. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
8. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
9. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
10. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
11. Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
(Date:8/18/2014)... August 19, 2014 2014 Deep ... is a professional and in-depth research report on ... Linalool information, including its definition, classification, application, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
(Date:8/18/2014)... Sterne, Kessler, Goldstein & Fox P.L.L.C. , an intellectual ... , announced today that it has filed eleven petitions ... U.S. Patent and Trademark Office (USPTO) on behalf of ... BRLI).  These IPR petitions aim to nullify eleven patents ... patents have been asserted against GeneDx in patent infringement ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company ... to regress atherosclerotic plaque, announced the recent presentation ... Division of Cardiology at the David Geffen School ... Heart Association (AHA) Scientific Sessions in Orlando, Florida.  ...
... 2011  If algae is to be the solution for America,s ... make that a reality. Applications are now available for continuing ... retrain workers as general science technicians in the rapidly expanding ... Approximately 55 students will begin classes in ...
... 22, 2011 Sequenom, Inc. (NASDAQ: SQNM ), ... announced the Company,s participation at the 23rd Annual Piper Jaffray ... November 29-30, 2011. Ronald M. Lindsay, Ph.D., ... Maier, CFO, will present on Tuesday, November 29, 2011 beginning ...
Cached Biology Technology:AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 3Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference 2
(Date:8/19/2014)... crocodiles colonised the seas during warm phases and became ... study which establishes a link between marine crocodilian diversity ... of more than 140 million years. , The ... de Lyon, France and formerly from the University of ... Communications ., Today, crocodiles are ,cold-blooded, animals that mainly ...
(Date:8/19/2014)... The University of Texas Health Science Center at San ... (UTSA) today announced the awarding of more than $750,000 ... (SALSI) Innovation Challenge. , Launched in 2003, SALSI is ... and an academic health science center join forces for ... funds collaborative studies, with a focus on public health ...
(Date:8/19/2014)... has been awarded a nearly $40,000 grant from the ... office of the National Park Service (NPS) and U.S. ... one-year study of the energy efficiency and cost effectiveness ... humid climates. , Radiant barriers are reflective thermal insulations ... back, thereby reducing the amount of heat emitted in ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... vegetative cover, strong winds, dry, non-cohesive sandy soils, ... resources of Abu Dhabi Emirate in the United ... stresses, including wind erosion, salinization, waterlogging, landfilling, and ... Dhabi Emirate, land degradation is a matter of ...
... have found a way to save time, money and ... shed light on the biological processes associated with all ... genetics, and postdoctoral associate Matthew C. Hale have provided ... necessary with recent advances in DNA sequencing technology. Instead, ...
... Pfizer Inc., a major biopharmaceutical company, and the Wisconsin ... licensing organization for the University of Wisconsin-Madison, announced May ... embryonic stem (hES) cell patents for the development of ... the rights to work with hES cells for drug ...
Cached Biology News:Wind, salt and water are leading indicators of land degradation in Abu Dhabi 2Random picks better than complicated process in gene identification 2WARF signs license agreement with Pfizer for human embryonic stem cells 2
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
...
Biology Products: